Novartis Xolair review continues
Executive Summary
"For the time being the review of E25 dossier in U.S. and in Europe is ongoing," Novartis Global Pharma Development Head Jorg Reinhardt said during the company's Oct. 11 teleconference. "The Pink Sheet" (Oct. 16, p. 14) incorrectly quoted Novartis as saying the review of the allergy/asthma monoclonal antibody therapy is on hold. Clinical trials of omalizumab are on hold after toxicity findings related to Xolair and a similar agent, E26 (1"The Pink Sheet" Sept. 18, In Brief)